
|Videos|June 8, 2017
Dr. Kelley on the Development of Biomarkers for HCC
Author(s)R. Kate Kelley, MD
R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses the development of biomarkers for patients with hepatocellular carcinoma (HCC).
Advertisement
R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses the development of biomarkers for patients with hepatocellular carcinoma (HCC).
The potential of many therapies in development depends on identifying the patient groups most likely to benefit, explains Kelley. This will require a better understanding of the biology of HCC.
According to Kelley, the potential of new therapies will drive a wave of research to further define the relevant subgroups.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































